Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects.
Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects.
复制标题
DOI：
10.4137/bcbcr.s7224
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Serrero G
中科院分区：
文献类型：
--
作者：
Tkaczuk KR;Yue B;Zhan M;Tait N;Yarlagadda L;Dai H;Serrero G
GP 88（PC-细胞衍生生长因子，颗粒蛋白前体）是一种在乳腺肿瘤中过表达的糖蛋白，并参与其增殖和存活。由于GP 88是分泌的，因此建立了一项探索性研究，以比较乳腺癌患者（BC）和健康志愿者（HV）之间的血清GP 88水平。一项IRB批准的前瞻性研究入组了189例1-4期BC患者和18例HV。通过免疫测定法测定GP 88血清浓度。HV患者血清GP 88水平为28.7 ± 5.8 ng/ml，1-3期患者血清GP 88水平升高至40.7 ± 16.0 ng/ml（P = 0.007），4期BC患者血清GP 88水平升高至45.3 ± 23.3 ng/ml（P = 0.0007）。GP 88水平与年龄、种族、肿瘤分级、ER、PR及HER-2表达等BC特征无相关性。这些数据表明，血清GP 88水平的系列测试可能具有作为用于检测、监测和随访BC的循环生物标志物的价值。
GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between breast cancer patients (BC) and healthy volunteers (HV). An IRB approved prospective study enrolled 189 stage 1–4 BC patients and 18 HV. GP88 serum concentration was determined by immunoassay. Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1–3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression. These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.